Avalon GloboCare Corp. Files 8-K

Ticker: ALBT · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1630212

Sentiment: neutral

Topics: corporate-update, business-classification

TL;DR

Avalon GloboCare Corp. filed an 8-K on 11/19/24, confirming its focus on biological products.

AI Summary

On November 19, 2024, Avalon GloboCare Corp. filed an 8-K report. The filing indicates that the company is a biological products company, not involved in diagnostic substances, and is incorporated in Delaware. The report details its principal executive offices located in Freehold, NJ.

Why It Matters

This 8-K filing provides an update on Avalon GloboCare Corp.'s corporate status and business classification, which is important for investors to understand the company's operational focus.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant financial or operational risks.

Key Players & Entities

FAQ

What is the primary business of Avalon GloboCare Corp.?

Avalon GloboCare Corp. is classified as a biological products company, specifically excluding diagnostic substances.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on November 19, 2024.

In which state is Avalon GloboCare Corp. incorporated?

Avalon GloboCare Corp. is incorporated in Delaware.

What is the address of Avalon GloboCare Corp.'s principal executive offices?

The principal executive offices of Avalon GloboCare Corp. are located at 4400 Route 9 South, Suite 3100, Freehold, NJ 07728.

What is the SIC code for Avalon GloboCare Corp.?

The Standard Industrial Classification (SIC) code for Avalon GloboCare Corp. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 661 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-11-21 09:00:14

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALON GLOBOCARE CORP. Dated: November 21, 2024 By: /s/ Luisa Ingargiola Name: Luisa Ingargiola Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing